Ozone Therapy for Blood Circulation: How It Works and What the Evidence Shows

Ozone therapy improves blood circulation through a well-documented biochemical mechanism: it increases 2,3-DPG levels in red blood cells, enhances red blood cell flexibility, and modulates nitric oxide production. These effects have been studied in patients with peripheral arterial disease, chronic venous insufficiency, and other circulatory disorders. While not a replacement for cardiovascular medications or surgical interventions, ozone therapy offers a complementary approach that addresses oxygen delivery at the cellular level.

This guide explains exactly how ozone affects circulation, what the clinical evidence shows, which modalities are used, and what treatment costs.

How Ozone Improves Blood Circulation

Ozone’s effects on circulation involve three distinct mechanisms, each supported by laboratory and clinical data.

1. The 2,3-DPG Effect

2,3-diphosphoglycerate (2,3-DPG) is a molecule found inside red blood cells that regulates how tightly hemoglobin holds onto oxygen. Higher 2,3-DPG levels cause hemoglobin to release oxygen more readily to surrounding tissues.

When ozone contacts blood during Major Autohemotherapy, it triggers a cascade of reactions that increases 2,3-DPG production. Bocci et al. demonstrated this in multiple studies, showing measurable increases in 2,3-DPG after a single MAH session.¹ The effect lasts approximately 20 days, which is roughly the halfway point of a red blood cell’s 120-day lifespan.

For patients with circulatory disorders, this is significant. Diseased blood vessels already deliver less blood to tissues. If the blood that does arrive can release its oxygen more efficiently, the net oxygen delivery to ischemic tissues improves even without increased blood flow.

2. Red Blood Cell Deformability

Healthy red blood cells are remarkably flexible. They can squeeze through capillaries narrower than their own diameter. In circulatory diseases, red blood cells often become rigid, further reducing blood flow through already compromised vessels.

Ozone treatment improves red blood cell membrane fluidity by modifying the lipid composition of cell membranes. Giunta et al. showed that after ozone autohemotherapy, red blood cells demonstrated improved deformability on laboratory testing.² More flexible cells navigate narrow and damaged blood vessels more effectively.

“Ozone therapy acts on the circulatory system through multiple pathways simultaneously: improving oxygen unloading from hemoglobin, increasing red cell flexibility, and stimulating nitric oxide. No single pharmaceutical addresses all three mechanisms at once.” Bocci V, Ozone: A New Medical Drug, 2011

3. Nitric Oxide Modulation

Nitric oxide (NO) is the body’s primary vasodilator. It relaxes smooth muscle cells in blood vessel walls, increasing blood flow. Endothelial dysfunction, where blood vessels lose their ability to produce adequate NO, is a hallmark of cardiovascular disease, diabetes, and aging.

Ozone therapy stimulates nitric oxide synthase (eNOS) activity in endothelial cells. This effect has been documented by several research groups and appears to persist for days after treatment.⁴ The result is improved vasodilation and blood flow in treated patients.

Clinical Evidence for Circulatory Conditions

Peripheral Arterial Disease (PAD)

PAD affects approximately 8.5 million Americans, causing reduced blood flow to the legs and feet. Symptoms range from intermittent claudication (leg pain when walking) to critical limb ischemia (rest pain and tissue loss).

The most-cited study is a randomized trial by Giunta et al. involving 28 patients with stage II PAD (intermittent claudication). Patients received either ozone autohemotherapy or oxygen autohemotherapy (placebo control) twice weekly for five weeks. The ozone group showed a 48% increase in pain-free walking distance compared to 18% in the control group.³

A larger observational study by Tylicki et al. followed 50 PAD patients receiving ozone therapy alongside standard medical management. After 20 sessions, ankle-brachial index (ABI) measurements improved in 72% of patients, and 65% reported subjective improvement in walking distance.⁵

Chronic Venous Insufficiency

Venous insufficiency causes blood to pool in the legs, leading to swelling, skin changes, and venous ulcers. Ozone therapy has been studied primarily for venous leg ulcers, where the combination of direct antimicrobial effects and improved local oxygenation promotes healing.

Topical ozone gas application (limb bagging) combined with ozonated oils has shown positive results in case series, with healing rates comparable to or better than standard compression therapy alone.⁶

Raynaud’s Phenomenon

Raynaud’s causes exaggerated vasoconstriction in fingers and toes in response to cold or stress. Small case series have reported improvements in symptom frequency and severity after ozone autohemotherapy. The proposed mechanism is improved endothelial function and nitric oxide production. However, controlled trials are lacking.

Which Ozone Modalities Are Used for Circulation

MAH is the most studied modality for circulatory conditions and the one most practitioners recommend as a first-line approach. 10-Pass and EBOO are reserved for more severe cases or patients who have not responded to standard MAH.

Treatment Protocols and Timeline

A typical protocol for circulatory conditions follows this pattern:

• Induction phase: 2 to 3 sessions per week for 4 to 6 weeks (8 to 18 sessions total)
• Maintenance phase: 1 session every 2 to 4 weeks for ongoing support
• Ozone concentration: 20 to 40 mcg/mL for MAH (lower concentrations used initially, gradually increased)

Most patients report noticeable improvements in symptoms after 6 to 8 sessions. Measurable changes in objective markers like walking distance and ABI typically appear after 10 to 15 sessions.

Cost Overview

Insurance does not cover ozone therapy for circulatory conditions. Some clinics offer package pricing with 10% to 20% discounts for prepaid session bundles.

Safety Considerations

Ozone therapy is generally well-tolerated when administered by trained practitioners. Adverse events documented in large case series (Jacobs, 1982: over 5.5 million sessions) are rare, occurring in fewer than 0.0007% of treatments.⁷

Specific considerations for patients with circulatory conditions:

• Blood thinners: Patients on anticoagulants (warfarin, heparin, DOACs) should inform their ozone practitioner. Ozone can affect blood viscosity, and protocols may need adjustment.
• G6PD deficiency: This is an absolute contraindication for ozone therapy. G6PD-deficient red blood cells cannot handle the oxidative stress and will hemolyze.
• Active bleeding: Ozone therapy should not be performed during active bleeding events.
• Hyperthyroidism: Uncontrolled hyperthyroidism is a relative contraindication due to increased metabolic activity.

The Bottom Line

Ozone therapy addresses blood circulation through multiple mechanisms that standard medications do not target: improved oxygen release from hemoglobin, increased red blood cell flexibility, and enhanced nitric oxide production. The evidence is most convincing for peripheral arterial disease, where randomized trials show measurable improvements in walking distance and limb perfusion. For other circulatory conditions, the evidence is promising but limited. Patients should view ozone as a complement to, not a replacement for, standard cardiovascular care.

References

1. Bocci V, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. Journal of Translational Medicine. 2011;9:66. doi:10.1186/1479-5876-9-66
2. Giunta R, Coppola A, Luongo C, et al. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Annals of Hematology. 2001;80(12):745-748. doi:10.1007/s002770100377
3. Giunta R, Coppola A, Luongo C, et al. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Annals of Hematology. 2001;80(12):745-748. doi:10.1007/s002770100377
4. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediators of Inflammation. 2000;9(6):271-276. doi:10.1080/09629350020027573
5. Tylicki L, Niewęgłowska-Goldsztajn K, Biedunkiewicz B, et al. Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs. International Journal of Artificial Organs. 2001;24(2):79-82.
6. Fitzpatrick E, Holland OJ, Vanderlelie JJ. Ozone therapy for the treatment of chronic wounds: A systematic review. International Wound Journal. 2018;15(4):633-644. doi:10.1111/iwj.12907
7. Jacobs MT. Untersuchung uber Zwischenfalle und typische Komplikationen in der Ozon-Sauerstoff-Therapie. OzoNachrichten. 1982;1:5-6.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website